CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 2.43: grey zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
16.80BTRY349.61M · vs all stocks (USD)
Revenue (TTM)
20.17BTRY419.76M · vs all stocks (USD)
Profit Margin
-4.84%Beta
-0.1300xvs all stocks
52-Week Change
25.56%vs all stocks
Market Capitalization
16.80BTRY349.61M · vs all stocks (USD)
Enterprise Value
20.53BTRY427.21M · vs all stocks (USD)
Price to Sales (TTM)
0.8839xPrice to Book (MRQ)
0.6182xEnterprise to Revenue
1.02xEnterprise to EBITDA
7.28xGross Margin
35.13%Profit Margin
-4.84%Operating Margin
18.56%Return on Assets (TTM)
1.98%Return on Equity (TTM)
-3.47%Revenue (TTM)
20.17BTRY419.76M · vs all stocks (USD)
Revenue per Share (TTM)
100.86TRYUpdated Aug 21, 2026Quarterly Revenue Growth
8.40%Gross Profit (TTM)
7.78BTRY161.79M · vs all stocks (USD)
EBITDA (TTM)
4.23BTRY87.99M · vs all stocks (USD)
Net Income (TTM)
-975.75MTRY-20.30M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-6.90%Operating Cash Flow (TTM)
513.07MTRY10.68M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-3.24BTRY-67.47M · vs all stocks (USD)
5-Year Average Dividend Yield
0.35%vs all stocks
Payout Ratio
0.00%Revenue
19.25BTRYFY2025 · Dec 31, 2025Cost of Goods Sold
12.94BTRYFY2025 · Dec 31, 2025Gross Profit
6.30BTRYFY2025 · Dec 31, 2025Operating Income
9.18MTRY191.05K · vs all stocks (USD)
Pre-tax Income
-92.71MTRYFY2025 · Dec 31, 2025Income Tax Expense
714.28MTRYFY2025 · Dec 31, 2025Net Income
-806.99MTRYFY2025 · Dec 31, 2025EBIT
2.64BTRYFY2025 · Dec 31, 2025EBITDA (Income Statement)
3.95BTRYFY2025 · Dec 31, 2025Research & Development
1.00BTRYFY2025 · Dec 31, 2025Selling, General & Administrative
1.56BTRYFY2025 · Dec 31, 2025Other Operating Expenses
118.02MTRYFY2025 · Dec 31, 2025Non-operating Interest Income
222.25MTRYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.73BTRYFY2025 · Dec 31, 2025Net Income from Continuing Operations
-806.99MTRYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TRYFY2025 · Dec 31, 2025Operating Cash Flow
-986.47MTRYFY2025 · Dec 31, 2025Free Cash Flow
-1.43BTRYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.38BTRYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-806.99MTRYFY2025 · Dec 31, 2025Other Non-cash Items
945.58MTRYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-2.16BTRYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.03BTRYFY2025 · Dec 31, 2025Capital Expenditures
-443.03MTRYFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.86BTRYFY2025 · Dec 31, 2025Other Investing Activity
1.94BTRYFY2025 · Dec 31, 2025Net Investing Cash Flow
1.50BTRYFY2025 · Dec 31, 2025Long-term Debt Issuance
15.15BTRYFY2025 · Dec 31, 2025Long-term Debt Payments
-15.77BTRYFY2025 · Dec 31, 2025Net Short-term Debt Issuance
551.93MTRYFY2025 · Dec 31, 2025Net Financing Cash Flow
-69.96MTRYFY2025 · Dec 31, 2025Shares Outstanding
200.02MSharesUpdated Aug 21, 2026Float Shares
35.59MSharesUpdated Aug 21, 2026% Held by Insiders
82.20%vs all stocks
% Held by Institutions
0.26%vs all stocks
Total Cash (MRQ)
3.57BTRY74.28M · vs all stocks (USD)
Total Cash per Share (MRQ)
17.85TRYUpdated Aug 21, 2026Total Debt (MRQ)
6.27BTRY130.46M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1988xCurrent Ratio (MRQ)
2.10xBook Value per Share (MRQ)
144.21TRYUpdated Aug 21, 2026Total Assets
37.63BTRY782.93M · vs all stocks (USD)
Total Current Assets
16.63BTRYFY2025 · Dec 31, 2025Total Liabilities
11.31BTRYFY2025 · Dec 31, 2025Total Non-current Assets
21.00BTRYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.23BTRYFY2025 · Dec 31, 2025Total Current Liabilities
10.07BTRYFY2025 · Dec 31, 2025Cash
741.66MTRYFY2025 · Dec 31, 2025Cash Equivalents
1.64BTRYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.38BTRYFY2025 · Dec 31, 2025Other Short-term Investments
1.21BTRYFY2025 · Dec 31, 2025Accounts Receivable
7.06BTRYFY2025 · Dec 31, 2025Inventory
5.43BTRYFY2025 · Dec 31, 2025Accounts Payable
2.70BTRYFY2025 · Dec 31, 2025Short-term Debt
5.30BTRYFY2025 · Dec 31, 2025Long-term Debt
679.34MTRYFY2025 · Dec 31, 2025Common Stock (Book)
200.02MTRYFY2025 · Dec 31, 2025Retained Earnings
18.56BTRYFY2025 · Dec 31, 2025Total Shareholders' Equity
26.32BTRY547.66M · vs all stocks (USD)
Treasury Stock
28.85KTRYFY2025 · Dec 31, 202552-Week Low
57.50TRYUpdated Aug 21, 202652-Week High
90.80TRYUpdated Aug 21, 202652-Week Change
25.56%vs all stocks
Beta
-0.1300xvs all stocks
50-Day MA
71.96TRYUpdated Aug 21, 2026200-Day MA
67.05TRYUpdated Aug 21, 2026Avg 10-Day Volume
1.11MSharesUpdated Aug 21, 2026Avg 30-Day Volume
686.09KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-4.04TRYUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.43: grey zoneSignificant
Altman Z-Score: 2.43
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Standard Biotools Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Cellectis S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Zhejiang Tailin Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Kangda New Materials Group Co., Ltd.
1 interpretationReceivables Heavy and Growing
Avery Dennison Corporation
1 interpretationReceivables Heavy and Growing
China Marine Information Systems Company Limited
1 interpretationReceivables Heavy and Growing